The Effect of Ascorbic Acid on Infection of Chick-Embryo Ciliated Tracheal Organ Cultures by Coronavirus

By

J. G. Atherton, C. C. Kratzing, and Anne Fisher
Departments of Microbiology and Physiology, University of Queensland, Brisbane, Australia.

With 1 Figure
Accepted August 10, 1977

Summary

Chick embryo tracheal organ cultures showed increased resistance to infection by a coronavirus after exposure to ascorbate, while chick respiratory epithelium and allantois-on-shell preparations showed no increase in resistance to infection by an influenza virus or a paramyxovirus.

Introduction

Recently it was established that the mucoid surface-film of lung alveolae contains a very high concentration of ascorbic acid. While there are difficulties in determining the ascorbic acid content of the surface film, it was estimated to be between 1.0 and 3.5 mg/ml (16). Because it was thought that these concentrations may behave as a defensive barrier, systems using monolayer cultures of chick-embryo respiratory epithelium, allantois-on-shell and chick-embryo ciliated tracheal organ (CETO) cultures were used to study the effect of ascorbic acid on virus infection. The viruses used were members of the Families Orthomyxoviridae (influenza A), Paramyxoviridae (Newcastle disease virus, NDV), and Coronaviridae (avian infectious bronchitis virus, IBV).

Materials and Methods

Respiratory epithelium cultures were prepared either in “Falcon” tissue culture flasks (30 ml) or in “Linbro” 96 cup polystyrene tissue culture microplates IS-FB-96-TC. Allantois-on-shell preparations were made by the method described by Fazekas and White (6).

CETO cultures were prepared by the method of Cherry and Taylor-Robinson (4) with minor modifications. The trachea were dissected out from 20 day-old chick-embryos and cut transversely into rings 1 mm thick. After washing, the rings were placed individually into tubes containing 3 ml of Eagle’s basal medium (BME) plus glutamine and antibiotics, buffered to pH 7.4. Full ciliary activity could be observed.
microscopically for up to 21 days when these cultures were maintained at 37° C, with
medium changes twice weekly.

The influenza virus, human influenza virus Type A, strain V73-1826, was obtained
from Commonwealth Serum Laboratories, Melbourne. The Paramyxovirus, Newcastle
disease virus, strain V4-10 and the Coronavirus, avian infectious bronchitis virus,
strain B-3125-1, were both isolated and identified by Mr. G. Simmons of the Animal
Research Institute, Brisbane.

Influenza virus and Newcastle disease virus titrations were performed either in
micro-cultures of chick respiratory epithelium or in allantois-on-shell preparations,
by inoculating 8 replicate cups with dilutions of virus made in half-log steps, then
incubating the preparations for 2 days at 37° C in a humidified chamber. Growth of
virus was detected by testing for haemagglutinin by the addition of 0.25 ml of a
5 per cent suspension of washed adult fowl red blood cells, after which the plates were
incubated at 4° C for 1 hour and then read for haemagglutinin using substage indirect
lighting. Virus end-points were then calculated as ID₅₀/ml by the Reed-Muench
method (12).

Titrations of avian infectious bronchitis virus were performed by inoculating
4 replicate chick-embryo tracheal organ culture tubes previously selected for ciliat
activity, with dilutions of virus made in half-log steps, then continuing to incubate
the preparations on a roller drum at 15 rev/hour at 37° C. These tubes were observed
daily for ciliat activity. Cilial activity was arbitrarially graded from 4+ to 0. The final
observation was made after 4 days incubation and cilial activity reduced to 1+ or
less taken as evidence of virus infection. Virus end-points were then calculated as
CETO ID₅₀/ml by the Reed-Muench method.

Ascorbic acid was estimated by the method of Bolin and Book (2). All ascorbic
acid solutions were used in neutralized form, without the addition of glutathione.

The uptake of ascorbic acid by cells was measured by exposing CETO cultures,
chick-embryo respiratory epithelial cultures and allantois-on-shell preparations
respectively to ascorbic acid in concentrations of 15–10,000 μg/ml for 2 hours at 37° C.
Samples of the cells were then taken for ascorbic acid determination and the remainder
used in viral infectivity tests. Tissue ascorbate concentrations obtained in CE respira-
tory epithelium and allantois-on-shell, were comparable with those of CETO (Table 1).

Cell culture medium to be tested for interferon was frozen and thawed once from
−20° C, adjusted to pH 2.2 with 1 M HCl, stored at 4° C for 24 hours, brought to
pH 7.2, and then centrifuged at 100,000×g for 1 hour. The supernatant was stored
at 4° C and tested for interferon activity within 48 hours. All interferon titrations were
performed against a standard preparation made by similar treatment of tissue culture
supernatant from NDV-infected chick embryo respiratory epithelial cell cultures.
Interferon titres were determined using a 50 per cent plaque reduction method similar
to that described by Moehring et al. (10) using West Nile virus in primary chick-
embryo fibroblast monolayers. Virus nomenclature used is that of Fenner (7).

**Results**

Three types of experiments were done:

1. Ascorbic acid in concentrations from 15 to 10,000 μg/ml was incubated
   with standard virus suspensions diluted in BME for from 1 to 3 hours at 37° C.
   A second series was held at 4° C. Results of infectivity assays were plotted graphi-
   cally and compared with those from virus suspensions made in BME alone. No
   significant effect of ascorbic acid on the rate of thermal inactivation of influenza
   virus, NDV or IB virus was observed.

2. In the second type of experiment virus and ascorbic acid were added to
cells at the same time and the ascorbate maintained throughout incubation.
Five dilution series of each virus were made at 4° C, one in BME alone and the
others in ascorbic acid dilutions of 15, 300, 1800 and 10,000 μg/ml. Each dilution
series was then used to perform virus infectivity titrations in the cell system appropriate for the virus under test. No significant effect on viral infectivity was observed.

3. In the third type of experiment, cells were exposed to ascorbic acid in concentrations of 15--10,000 μg/ml for 2 hours at 37°C. Samples of cells were taken for determination of ascorbic acid content and the remainder used in viral infectivity tests. Simultaneous parallel virus titrations were performed on cells which had not been exposed to ascorbic acid.

The resistance of cells to infection was measured by exposing them to half-log dilutions of a standard virus suspension, incubating, and then calculating the virus infectivity end-point.

A lower titre for virus infectivity end-point in treated cells compared with untreated cells, indicating a decrease in plating efficiency, was taken as evidence of increased resistance of the treated cells to virus infection.

Increasing cell content of ascorbic acid did not increase the resistance of cells to infection by influenza or Newcastle disease viruses. However resistance of CETO cultures to IB virus infection rose with increasing ascorbic acid content (Table 1 and Fig. 1). Tissue containing 10^{3.6} μg/ml (3980 μg/ml) of ascorbate showed a virus infectivity end-point of 10^{2.5} CETO ID_{50}/ml compared with 10^{3.7} CETO ID_{50}/ml for tissues without ascorbate, i.e. a 15.8 times larger dose was needed to infect tissues containing ascorbate, with IB virus.

Reports of induction of increased serum concentrations of interferon in vivo by ascorbate (8, 11, 14, 15) prompted tests for interferon in the experiments cited. CETO cultures were treated with 10,000 μg/ml of ascorbate for 2 hours, then infected with IB virus dilutions from 10^{2}--10^{4.5} CETO ID_{50}/ml for 72 hours at

![Resistance of CETO cultures to Infection by IB virus](image)

Fig. 1. The infectivity end-points of a standard preparation of Coronavirus (IBV) were determined in tissues containing increasing amounts of ascorbic acid. Tissue containing 10^{3.6} μg/ml ascorbic acid required 15.8 times the virus to produce infection compared to tissues without ascorbate. After cells had been pretreated with exogenous interferon the virus dose necessary to cause infection was approximately doubled.
37°C. The fluids were then assayed for interferon by a plaque-reduction test using West Nile virus in chick-embryo fibroblast monolayers. No significant differences in interferon content could be detected between fluid from cells alone, cells plus ascorbate, and virus-infected cells with and without ascorbate.

Standard interferon prepared as described above had a 50 per cent plaque reduction (PR50) titre of 1:132. The effect of interferon-plus ascorbic acid was tested by adding an interferon preparation diluted 1:66 (twice the PR50 concentration) to CETO cultures exposed to varying ascorbic acid concentrations and incubating at 37°C for 2 hours. These CETO cultures were then infected with $10^{3.7}$ CETO ID$_{50}$/ml IB virus and the infectivity end-points determined. The results are shown in Table 1 and Figure 1.

Differences between mean titres obtained with and without interferon in the presence of ascorbate, although little greater than the s.e., suggest that interferon exerted a slight effect, i.e. about doubling cell resistance to virus. This effect is very small compared with that of ascorbate.

Table 1. Resistance of CETO cultures to infection by IB virus in the presence of ascorbic acid with and without exogenous interferon

| Pretreatment of cells | Tissue conc. of ascorbate reached log$_{10}$ μg/g | Virus titre log$_{10}$ CETO ID$_{50}$/ml mean stand. error |
|----------------------|-----------------------------------------------|----------------------------------------------------------|
| None                 | Nil                                           | 3.7±0.21                                                 |
| Ascorbate            |                                               |                                                          |
| 15 μg/ml             | 1.14                                          | 3.5±0.20                                                 |
| 300 μg/ml            | 2.29                                          | 3.1±0.18                                                 |
| 1,000 μg/ml          | 2.66                                          | 2.8±0.18                                                 |
| 10,000 μg/ml         | 3.59                                          | 2.5±0.19                                                 |
| Interferon 1:66      | Nil                                           | 3.3±0.20                                                 |
| Interferon 1:66 + Ascorbate |                      |                                                          |
| 15 μg/ml             | 1.14                                          | 3.2±0.19                                                 |
| 300 μg/ml            | 2.29                                          | 2.9±0.19                                                 |
| 1,000 μg/ml          | 2.66                                          | 2.6±0.17                                                 |
| 10,000 μg/ml         | 3.59                                          | 2.3±0.17                                                 |

Discussion

SCHWERDT and SCHWERDT (14) showed that exposure of WI-38 cells to ascorbic acid plus glutathione mixtures for 2 days prior to infection with rhinovirus suppressed multicyclic but not single cycle growth. The same authors found some evidence for barely detectable levels of interferon at high virus MOI.

MURPHY et al. (11) found that increased amounts of ascorbate were unable to prevent parainfluenza virus 3 experimental infection or primary immune response in cotton-topped marmosets. However the onset of disease was delayed, clinical responses reduced and mortality decreased in animals fed doses of ascorbic acid equivalent to 35 g/day for man. On the other hand, SCHWARTZ et al. (13) followed a number of parameters of virus infection and disease in a group of human volunteers infected with rhinovirus 44, but were unable to show any differences between controls and those treated with ascorbic acid.
Our results show that ascorbic acid exerted no direct effect on the infectivity of any of the three viruses tested, nor did it affect the resistance of cells to infection by the Orthomyxovirus (influenza) or the Paramyxovirus (NDV). However, CETO cultures previously exposed to ascorbic acid exhibited considerably increased resistance to infection by Coronavirus (IBV). These results suggest that different mechanisms operate for infection of cells by viruses of these different groups.

The different effects of ascorbate on experimental infection by viruses from different groups suggest that, when clinical trials of the effect of ascorbate on respiratory virus infection are conducted (1, 3, 5, 9) it is important to ascertain to which group the infecting virus belongs.

References

1. Anderson, T. W., Beaton, G. G., Corey, P., Spiero, L.: Winter illness and vitamin C: The effect of relatively low dose. Canad. Med. Assoc. J. 112, 823—826 (1975).
2. Bolin, D. W., Book, L.: Oxidation of ascorbic acid to dehydroascorbic acid. Science 160, 451 (1947).
3. Chalmers, T. C.: Effects of ascorbic acid on the common cold: An evaluation of the evidence. Amer. J. Med. 58, 532—536 (1975).
4. Cherry, J. D., Taylor-Robinson, D.: Large-quantity production of chicken embryo tracheal organ cultures and use in viral and mycoplasma studies. Appl. Microbiol. 19, 658—662 (1970).
5. Dykes, M. H., Meier, P.: Ascorbic acid and the common cold: Evaluation of its efficacy and toxicity. J. Amer. Med. Assoc. 231, 1073—1079 (1975).
6. Fazekas de St. Groth, S., White, D. O.: An improved assay for the infectivity of influenza viruses. J. Hyg. 56, 151—163 (1958).
7. Fenner, F.: Classification and nomenclature of viruses. Second Report of the International Committee on Taxonomy of Viruses. Intervirology 7, 4—115 (1976).
8. Géber, W. F., Leffkowitz, S. S., Hung, C. Y.: Effect of ascorbic acid, sodium salicylate and caffeine on the serum interferon level in response to viral infection. Pharmacology 13, 228—233 (1975).
9. Karlowski, T. R., Chalmers, T. C., Frenkel, L. D., Kapikian, A. Z., Lewis, T. L., Lynch, J. M.: Ascorbic acid for the common cold: A prophylactic and therapeutic trial. J. Amer. Med. Assoc. 231, 1038—1042 (1975).
10. Moehring, J. M., Stinebring, W. R., Merchant, D. J.: Survey of interferon production and sensitivity in human cell lines. Appl. Microbiol. 22, 102—105 (1971).
11. Murphy, B. L., Krushak, D. H., Maynard, J. E., Bradley, D. W.: Ascorbic acid (vitamin C) and its effects on parainfluenza type 3 virus infection in cotton-topped marmosets. Lab. Anim. Sci. 24, 229—232 (1974).
12. Reed, L. J., Muench, H.: A simple method of estimating fifty per cent endpoints. Amer. J. Hygiene 27, 493—497 (1938).
13. Schwartz, A. R., Togo, Y., Hornick, R. B., Tominaga, S., Glickman, R. A.: Evaluation of the efficacy of ascorbic acid in prophylaxis of induced rhinovirus 44 infection in man. J. Inf. Dis. 128, 500—505 (1973).
14. Schwerdt, P. R., Schwerdt, C. E.: Effect of ascorbic acid on rhinovirus replication in W1-38 cells. Proc. Soc. exp. Biol. Med. 148, 1237—1243 (1975).
15. Siegel, B. V.: Enhanced interferon response to murine leukemia virus by ascorbic acid. Infect. Immun. 10, 409—410 (1974).
16. Willis, R. J., Kratzing, C. C.: Ascorbic acid in rat lung. Biochem. biophys. Res. Comm. 59, 1250—1253 (1974).

Authors' address: Dr. J. G. Atherton, Department of Microbiology, University of Queensland, St. Lucia, Brisbane 4067, Australia.

Received May 23, 1977